New strategy for COVID-19 vaccination: targeting the receptor

Vaccines, Free Full-Text

Frontiers Potential Therapeutic Targets and Vaccine Development

Immune Network

Strategies for the development and approval of COVID-19 vaccines

Covid Nasal Vaccines Get A Boost - by Eric Topol

Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunogenicity of SARS-CoV-2 Receptor-Binding Domain Vaccine

Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunogenicity of SARS-CoV-2 Receptor-Binding Domain Vaccine

Researchers develop a nasal vaccine that prevents COVID-19 in

PDF) Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2

Mutant Gene-Targeted Immunotherapy Approach Developed

Frontiers Will Host Genetics Affect the Response to SARS-CoV-2

COVID-19 vaccine: A recent update in pipeline vaccines, their